These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 9737324)

  • 1. Mibefradil: the sole exception.
    Weerasuriya K
    Lancet; 1998 Sep; 352(9130):823-4. PubMed ID: 9737324
    [No Abstract]   [Full Text] [Related]  

  • 2. Mibefradil withdrawn from the market.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998; 32(7-8):841. PubMed ID: 9681103
    [No Abstract]   [Full Text] [Related]  

  • 3. Mibefradil release expands calcium-channel-blocker choices.
    Am J Health Syst Pharm; 1997 Sep; 54(18):2033. PubMed ID: 9377200
    [No Abstract]   [Full Text] [Related]  

  • 4. What lessons can be learnt from withdrawal of mibefradil from the market?
    Po AL; Zhang WY
    Lancet; 1998 Jun; 351(9119):1829-30. PubMed ID: 9652662
    [No Abstract]   [Full Text] [Related]  

  • 5. Mibefradil and an effective formulary system.
    Vermeulen LC; Dunham DB
    Am J Health Syst Pharm; 1998 Sep; 55(18):1934-5. PubMed ID: 9784776
    [No Abstract]   [Full Text] [Related]  

  • 6. Withdrawal of Posicor from market.
    SoRelle R
    Circulation; 1998 Sep; 98(9):831-2. PubMed ID: 9738634
    [No Abstract]   [Full Text] [Related]  

  • 7. Mibefradil--a new calcium-channel blocker.
    Med Lett Drugs Ther; 1997 Nov; 39(1013):103-5. PubMed ID: 9391500
    [No Abstract]   [Full Text] [Related]  

  • 8. The withdrawal of mibefradil (Posicor).
    Griffin JP
    Adverse Drug React Toxicol Rev; 1998; 17(2-3):59-60. PubMed ID: 9838964
    [No Abstract]   [Full Text] [Related]  

  • 9. Mibefradil: a new twist to the calcium channel antagonist.
    Lynn MM
    Nurse Pract; 1998 May; 23(5):100, 102-4, 106-7. PubMed ID: 9614683
    [No Abstract]   [Full Text] [Related]  

  • 10. Roche cites drug interactions in mibefradil withdrawal.
    Am J Health Syst Pharm; 1998 Jul; 55(14):1445. PubMed ID: 9676286
    [No Abstract]   [Full Text] [Related]  

  • 11. [Mibefradil: a new class calcium inhibitor].
    Internist (Berl); 1996 Oct; 37(10 Suppl Mibefradil):1-8. PubMed ID: 9402420
    [No Abstract]   [Full Text] [Related]  

  • 12. [Introducing mibefradil--a new T-calcium channel blocker].
    Internist (Berl); 1997 Dec; 38(12 Suppl Mibefradil):1-4. PubMed ID: 9437250
    [No Abstract]   [Full Text] [Related]  

  • 13. Mibefradil (posicor).
    Giles TD
    Compr Ther; 1997 Nov; 23(11):761-3. PubMed ID: 9360806
    [No Abstract]   [Full Text] [Related]  

  • 14. Comment: mibefradil, a new class of calcium-channel antagonists.
    Otterman S
    Ann Pharmacother; 1998 Dec; 32(12):1372. PubMed ID: 9876826
    [No Abstract]   [Full Text] [Related]  

  • 15. [Induction of bradycardia by mibefradil in antihypertensive combination therapy].
    Wagner J; Ritz E
    Dtsch Med Wochenschr; 1998 Apr; 123(17):547. PubMed ID: 9601479
    [No Abstract]   [Full Text] [Related]  

  • 16. Roche, FDA announce new drug-interaction warnings for mibefradil.
    Am J Health Syst Pharm; 1998 Feb; 55(3):210. PubMed ID: 9492249
    [No Abstract]   [Full Text] [Related]  

  • 17. Short-term hemodynamic effects of mibefradil in dogs with chronic heart failure: comparison with diltiazem.
    Shimoyama H; Sabbah HN; Tanimura M; Borzak S; Goldstein S
    J Pharmacol Exp Ther; 1998 May; 285(2):746-52. PubMed ID: 9580622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rhabdomyolysis due to interaction of simvastatin with mibefradil.
    Schmassmann-Suhijar D; Bullingham R; Gasser R; Schmutz J; Haefeli WE
    Lancet; 1998 Jun; 351(9120):1929-30. PubMed ID: 9654265
    [No Abstract]   [Full Text] [Related]  

  • 19. Profound symptomatic bradycardia associated with combined mibefradil and beta-blocker therapy.
    Rogers R; Prpic R
    Med J Aust; 1998 Oct; 169(8):425-7. PubMed ID: 9830391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967).
    Bezprozvanny I; Tsien RW
    Mol Pharmacol; 1995 Sep; 48(3):540-9. PubMed ID: 7565636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.